Alfred Slanetz
President & Chief Executive Officer Geneius
Alfred Slanetz is the Chief Executive Officer of Geneos Therapeutics, where he leads the development of personalized cancer immunotherapies based on neoantigen vaccines. He is an experienced biotechnology executive with a strong background in corporate strategy, finance, and company building, having held leadership roles at several life sciences companies. Throughout his career, he has focused on advancing innovative therapies from early-stage research through clinical development and commercialization.
Seminars
Wednesday 22nd July 2026
Exploring the Advantages & Disadvantages of Combination Therapies in Improving Clinical Trial Outcomes & Tumour Targeting
4:00 pm
- Evaluating how combination therapies can enhance tumour-specific immune responses
- Overcoming challenges with increased toxicity, complex dosing schedules, and variable patient responses to maximise effectiveness of combined regimens
- Discussing strategies to optimise trial design, biomarker selection, and patient stratification to maximise the benefits of combination therapies
